

Anti- Human LAMBDA (Polyclonal F'ab 2)

Fluorochrome	Reference	Test
PE	LPE2-100T	100 test
FITC	LF2-100T	100 test



PRODUCT DESCRIPTION

Clone: Polyclonal

Isotype: Rabbit F(ab')₂ IgG

Tested application: flow cytometry

Immunogen: Polyclonal immunoglobulin light chains of Lambda type isolated from a pool of human sera.

Species reactivity: Human

Storage instruction: store in the dark at 2-8 °C

Storage buffer: aqueous buffered solution containing protein stabilizer and 0.09% sodium azide (NaN₃).

Recommended usage: Immunostep's Lambda F(ab')₂, is intended for simultaneous detection and enumeration of B lymphocytes bearing lambda light chains in peripheral blood using flow cytometry. This reagent is effective for direct immunofluorescence staining of human tissue for flow cytometric analysis using 10 µl/10⁶ cells.

Presentation: Liquid.

Rabbit polyclonal antibody directed against human lambda light chains, conjugated to a fluorochrome. Supplied in an aqueous solution containing a stabilizing protein and 0.09% sodium azide (NaN₃) as a preservative.

Fluorochrome	Supplied reagent	Concentration (mg/ml)	Volume/test
FITC	100 test	0.15	10 µL
PE	100 test	0.1	10 µL

Source: Supernatant proceeding from sera for Rabbit Anti-Human Lambda Light Chains.

Purification: Affinity chromatography.

CLINICAL RELEVANCE

This marker can be used alone or in combination with other B-cell markers for the diagnosis and monitoring of various hematologic malignancies and immunodeficiencies. Anti-kappa/lambda antibodies are essential in the immunophenotypic analysis of B-cell populations, enabling the detection of light chain expression patterns that help distinguish between polyclonal and monoclonal B-cell expansions.

In healthy individuals, B cells express either kappa or lambda light chains in a relatively stable ratio (typically around 2:1 in favor of kappa). A significant deviation from this ratio, particularly the presence of a dominant lambda-expressing population, is indicative of B-cell clonality, a hallmark of malignancies such as chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphomas, and multiple myeloma.

Flow cytometric analysis using anti-lambda antibodies is also valuable in the evaluation of immunodeficiencies, where B-cell development or function may be impaired. Additionally, it supports the differentiation between

reactive polyclonal responses and neoplastic monoclonal proliferations, which is critical for accurate diagnosis, prognosis, and therapeutic decision-making.

ANTIGEN DETAILS

Large description: The evaluation of cell surface Kappa/Lambda expression can identify clonally restricted B lymphocyte populations and thus can aid in the diagnosis of hematologic malignancy. Several B cell disorders are associated with decreased levels of Kappa/Lambda at the cell surface.⁽¹⁻⁴⁾

PRINCIPLES OF THE TEST

The anti-human lambda polyclonal antibody binds specifically to lambda light chains expressed on the surface or in the cytoplasm of B cells. To identify these cells, the sample is incubated with the fluorochrome-conjugated antibody and analyzed by flow cytometry. The fluorescence intensity reflects the presence and relative abundance of lambda light chains, allowing for the characterization of B-cell populations and the assessment of clonality.

APPROPRIATE STORAGE AND HANDLING CONDITIONS

Store in the dark, refrigerated between 2 °C and 8 °C. DO NOT FREEZE. The antibody is stable until the expiry date stated on the vial label if kept at 2°C-8°C. Do not use after the date indicated.

Once the vial is open, the product is stable for 90 days.

EVIDENCE OF DETERIORATION

Reagents should not be used if any evidence of deterioration is observed. For more information, please contact our technical service: tech@immunostep.com. The product's normal appearance is a semi-transparent, colourless liquid. It should not be used if liquid medium is cloudy or contains precipitate. It should be odourless.

RECOMMENDATIONS AND WARNINGS



- The reagents contain sodium azide. In acid conditions, it is transformed into hydrazoic acid, a highly toxic compound. Azide compounds must be diluted in running water before being discarded. These conditions are recommended so as to avoid deposits in plumbing, where explosive conditions could develop. The safety data sheet (SDS) is available online at www.immunostep.com
- Avoid microbial contamination of the reagent.
- Protect from light. Use dim light during handling, incubation with cells and prior to analysis.
- Never mouth pipette.
- In the case of contact with skin, wash in plenty of water.
- The samples should be handled in the same way as those capable of transmitting infection. Appropriate handling procedures should be guaranteed.
- Do not use after the expiry date indicated on the vial.
- Deviations from the recommended procedure could invalidate the analysis results.
- FOR *IN VITRO* DIAGNOSTIC USE.
- For professional use only.

- k) Before acquiring the samples, it is necessary to make sure that the flow cytometer is calibrated and compensated.

SAMPLE COLLECTION

The extraction of venous blood samples should be carried out in blood collection tubes using the appropriate anticoagulant (EDTA or heparin)^{7,8}. For optimum results, the sample should be processed during the six hours following the extraction. Samples which cannot be processed within the 48 hours following the extraction should be discarded.

Please, refer to www.immunostep.com technical support for more information.

WARRANTY

Warranted only to conform to the quantity and contents stated on the label or in the product labelling at the time of delivery to the customer. Immunostep disclaims hereby other warranties. Immunostep's sole liability is limited to either the replacement of the products or refund of the purchase price.

1. MATERIALS REQUIRED BUT NOT PROVIDED

- Centrifuge
- Commonly used 12 x 75-mm flow cytometry assay tubes
- Micropipettes for dispensing volumes from 5 µL to 2 mL
- Blood collection tubes with anticoagulant.
- Phosphate buffered saline (PBS) with 0.09% sodium azide. It is recommendable to add 0.5% BSA
- Vacuum system
- Lysing solution (Ref. RBC-10X)
- Flow cytometer equipped with laser and appropriate fluorochrome filters
- Vortex Agitator

2. SAMPLE PREPARATION: PROCEDURE WITH PRE-WASH

1. Pipette 300 µL of sample into a 10 mL Falcon tube.
2. Add 6 mL of washing buffer and mix well, preferably by gently vortexing.
3. Fill the tube up to 10 mL by adding an additional 4 mL of washing buffer.
4. Mix well again by gently vortexing.
5. Centrifuge at 540 g for 5 minutes.
6. Carefully discard the supernatant using a Pasteur pipette or vacuum system, avoiding disturbance of the cell pellet.
7. Resuspend the pellet gently.
8. Repeat steps 2 to 7 two more times (for a total of three washing steps).
9. After the final wash, resuspend the cell pellet in 300 µL of washing buffer.
10. Continue with the standard protocol for staining of surface or intracellular antibodies.

Note 1: For small volume samples (e.g., cerebrospinal fluid or vitreous aspirates), centrifuge the entire volume at 540 g for 5 minutes, discard the supernatant, and resuspend in 300 µL of washing buffer before proceeding.

Acquire on a flow cytometer or store in the dark at 2°C -8°C until the analysis is carried out. Samples should be acquired within the 3 hour after lysis.

3. FLOW CYTOMETRY ANALYSIS

Collect the fluorescence attributed to antibody and determine the percentage of positive cells. It is necessary to use an isotope control conjugated with the same fluorochrome, of the same type of immunoglobulin and concentration, so as to evaluate and correct the unspecific binding of lymphocytes (*please see materials required but not provided*). Set an analysis region to eliminate fluorescence background noise and to include positively **labelled** cells.

4. LIMITATIONS OF THE PROCEDURE

1. Incubation of antibody with cells for other than the recommended procedures may result in a reduction or loss of antigenic determinants from the cell surface.
2. The values obtained from normal individuals may vary from laboratory to laboratory; it is therefore suggested that each laboratory should establish its own normal reference range.
3. Abnormal cells or cell lines may show a higher antigen density than normal cells. In some cases, this could require the use of a greater quantity of monoclonal antibody than is indicated in the procedures for sample preparation.
4. In whole blood samples, red blood cells found in abnormal samples, as well as nucleated red cells (from both normal and abnormal specimens) may be resistant to lysis. Longer periods of red blood cell lysing may be needed in order to avoid the inclusion of unlysed cells in the lymphocyte gated region.
5. Blood samples should not be refrigerated for an extensive period (more than 24 hours), since the number of viable cells will gradually decrease, and this may have an effect on the analysis. In order to obtain the best values, they should be kept at room temperature immediately prior to incubation with the monoclonal antibody.
6. Accurate results with flow cytometric procedures depend on correct alignment and calibration of the lasers, as well as correct gate settings.

5. REFERENCE VALUES

Abnormal results in the percentage of cells expressing the antigen or in its levels of expression may be due to pathological conditions. It is advisable to know the normal antigen expression patterns in order to ensure a proper interpretation of the results^{4,5,6}.

The values obtained from healthy individuals may vary from laboratory to laboratory; it is therefore suggested that each laboratory should establish its own normal reference range.

The mean fluorescence intensity (MFI) was calculated for each dilution level. The results demonstrated a strong linear relationship between the dilution level and the MFI, with a coefficient of determination (R^2) of 0.99, indicating excellent linearity across the tested range.

6. CHARACTERISTICS

SPECIFICITY

Rabbit polyclonal antibodies against human lambda light chains specifically recognize the lambda subunit of immunoglobulins, which is expressed on the surface of approximately one-third of mature B lymphocytes in peripheral blood, as well as on a subset of immature B cells in bone marrow.

1. Cell Population Profiling

To evaluate analytical specificity, a comparative study was conducted using a multicolor flow cytometry panel including the test antibody (Immunostep) and a reference antibody. Peripheral blood samples from healthy donors were analyzed to assess marker expression across various leukocyte subsets.

The test antibody showed strong and specific staining of CD19⁺ B cells, with a mean positivity of 30.9% and low variability (CV = 3.11%). Subsets such as naïve (CD27⁻/IgD⁺) and memory B cells (CD27⁺/IgD⁻) were also clearly identified, confirming the antibody's ability to detect lambda light chains across different stages of B-cell maturation. Minimal or no staining was observed in T cells, NK cells, and granulocytes, supporting the antibody's specificity.

Notably, plasmacytoid dendritic cells (CD123⁺/HLA-DR⁺) and monocyte-derived dendritic cells (CD16⁻/CD14⁻) also showed high positivity, consistent with known expression patterns of surface immunoglobulins in certain antigen-presenting cell subsets.

2. Blocking Assay

To further confirm specificity, a blocking experiment was performed using the Dako polyclonal anti-lambda F(ab')₂ antibody. Samples were co-stained with both the test and reference antibodies in reciprocal combinations. No complete blocking was observed, indicating that the antibodies bind to distinct or non-overlapping epitopes, as expected for polyclonal reagents.

These results confirm the analytical specificity of the anti-lambda antibody for flow cytometric applications, supporting its use in the identification of B-cell subsets, assessment of clonality, and evaluation of immunodeficiencies.

SENSIBILITY

The analytical sensitivity of the anti-lambda PE antibody was evaluated using a serial dilution model with Daudi (lambda⁺) and Namalwa (lambda⁺) cell lines. Each dilution was adjusted to a final concentration of 1×10^5 cells per tube, and analyzed in duplicate across nine concentration levels, following the statistical approach described in the CLSI guideline "Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline", Appendix C.

Marker	R ²	LoB %	LoD %	LoQ %
FITC	0.999	1.73	2.01	6.41
PE	0.996	0.647	0.656	4.2

The Limit of Blank (LoB), the Limit of Detection (LoD) and the Limit of Quantification (LoQ) confirm the assay's high sensitivity and reliable quantification at low concentration levels.

These findings confirm that the antibody provides a reliable and proportional signal across a wide range of antigen concentrations, supporting its use in quantitative flow cytometric applications.

PRECISION

Precision was assessed following the CLSI EP05-A3 guideline using a 3x3x2x3 study design, which included three levels of samples (low, medium, high), three independent reagent lots, two Cytex Aurora flow cytometers, and three replicates per condition. The study did not include variability across days. Data acquisition was performed on the Cytex Aurora instruments, and analysis was conducted using the Infinicyt™ software (BD Biosciences). This design enabled the evaluation of both repeatability (within-run precision) and intermediate precision across instruments and reagent lots under controlled laboratory conditions.

Repeatability

To assess intra-assay variability and repeatability, three replicates per sample level were analyzed across three reagent lots and two Cytex Aurora flow cytometers, resulting in a total of 54 measurements per sample level. The standard deviation (SD) and coefficient of variation (CV%) were calculated for each condition using data processed in Infinicyt™ (BD Biosciences), providing a robust estimate of repeatability under controlled laboratory settings.

Marker	Repeatability SD	Repeatability %CV	Within-site SD	Within-site %CV
FITC	0.66	1.5	0.46	1.1
PE	1.59	4.2	2.56	5.2

These results demonstrate excellent repeatability and consistent performance across different reagent lots and testing conditions within the same laboratory under controlled laboratory conditions.

Between-Laboratory Precision

Between-laboratory precision was evaluated by analyzing three replicates per sample level. Although the study did not include day-to-day variability, the use of two independent instruments and multiple reagent lots allowed for the estimation of intermediate precision under controlled inter-laboratory conditions. Data were analyzed and the standard deviation (SD) and coefficient of variation (CV%) were calculated to characterize the variability attributable to instrumentation and reagent lot differences. The variability between lab and lot was negligible, with:

Marker	Between-lab SD	Between-lab %CV	Between-lot SD	Between-lot %CV

Marker	Between-lab SD	Between-lab %CV	Between-lot SD	Between-lot %CV
FITC	0	0	1.72	2.6
PE	1.55	3.99	2.43	3.7

This confirms the consistency of the antibody performance across different production batches and labs.

Reproducibility

Reproducibility was assessed by evaluating three replicates per sample level across three reagent lots and two Cytek Aurora flow cytometers, totaling 54 measurements per sample level. Although the study did not include inter-day or inter-operator variability, the use of multiple instruments and reagent lots across laboratories provided a meaningful estimate of reproducibility under controlled multi-laboratory conditions. Data analysis was performed using Infinicyt™ (BD Biosciences), and the standard deviation (SD) and coefficient of variation (CV%) were calculated to quantify the overall variability attributable to laboratory and equipment differences.

Reproducibility was assessed using stabilized samples processed at multiple laboratories. The reproducibility were as follows:

Marker	Reproducibility SD	Reproducibility %CV
FITC	0.63	1.5
PE	4.48	10.2

These results confirm that the antibody provides consistent and reproducible staining across different testing conditions.

7. WARRANTY

Warranted only to conform to the quantity and contents stated on the label or in the product labelling at the time of delivery to the customer. Immunostep's sole liability is limited to either the replacement of the products or refund of the purchase price.

8. BIBLIOGRAPHY

1. Procedures for the collection of diagnostic blood specimens by venipuncture- approved standard; Fifth edition (2003). Wayne PA: National Committee for Clinical Laboratory Standards; Document H3-A5.
2. Standard Procedures for the Collection of Diagnostic Blood Specimens", publicado por el National Committee for Clinical Laboratory Standards (NCCLS)
3. Clinical applications of flow cytometry: Quality assurance and immunophenotyping of lymphocytes; approved guideline (1998). Wayne PA: National Committee for Clinical Laboratory Standards; Document H42-A.
4. Kotylo PK et al. Reference ranges for lymphocyte subsets in pediatric patients. Am J Clin Pathol 100:111-5 (1993)
5. Reichert et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 60:190-208 (1991)
6. Malcolm S, Barton P, Murphy C, Ferguson-Smith MA, Bentley DL, Rabbitts TH. Localization of human

immunoglobulin kappa light chain variable region genes to the short arm of chromosome 2 by in situ hybridization. Proc Natl Acad Sci U S A. 1982 Aug;79(16):4957-61.

7. Orfao A, Matarraz S, Pérez-Andrés M, Almeida J, Teodosio C, Berkowska MA, van Dongen JJM; EuroFlow. Immunophenotypic dissection of normal hematopoiesis. J Immunol Methods. 2019 Dec;475:112684.
8. CLSI EP05-A3. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline-Third Edition.
9. Rijkers GT1, Scharenberg JG, Van Dongen JJ, Neijens HJ, Zegers BJ. Abnormal signal transduction in a patient with severe combined immunodeficiency disease. Pediatr Res. 1991 Mar;29
10. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986 Dec 19.

9. MANUFACTURED BY

Immunostep S.L

Avda. Universidad de Coimbra, s/n
Cancer Research Center (CIC)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. (+34) 923 294 827
www.immunostep.com

9. SURVEILLANCE AND NOTIFICATION



In accordance with Annex I, Section 20.4.1(n) of Regulation (EU) 2017/746, the user is obliged to report any serious incident related to the use of the product.

- **To the Manufacturer:** Please contact our Surveillance Department at vigilancia@immunostep.com
- **To the Competent Authority:** Report via the official channels of the Member State.

10. EXPLANATION OF SYMBOLS

	CE labeling
	In vitro diagnostic device
	Manufacturer
	Pay attention to